This report was first published by Endpoints News. To see the original version, click here
There’s a reason lots of companies are working on GLP-1-based drugs for obesity: The other stuff tends not to work. The latest biotech to learn this the hard way is Wave Life Sciences, which said Thursday that its obesity candidate yielded weight loss of just 1% more than placebo in an early-stage study.
The company’s stock $WVE tanked more than 55% when trading opened on Thursday morning.
您已阅读15%（481字），剩余85%（2796字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。